Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Access to innovative medicines remains a critical issue in healthcare. Teva Pharmaceuticals is tackling this challenge head-on, driving scientific innovation to deliver high-quality medicines that ...

Teva delivered 3.4% revenue growth and $0.78 in adjusted EPS during the third quarter, beating consensus estimates by a low-single-digit and midteens percentage, respectively. The market reacted very ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue ...

Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing ...

YARAL Pharma Inc. (Parsippany, NJ) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. Committed to advancing healthcare through high-quality ...

Glycerol phenylbutyrate oral liquid is indicated for the chronic management of patients with urea cycle disorders. Sims added, "It expands access for patients and providers, and reinforces our ...

Generic drugmakers continue to navigate a challenging U.S. market defined by persistent price erosion, intense competition and structurally thin margins. While demand for generics remains steady, ...